Jeremy Broadis of Quintiles looks at how specialist pharma companies can evaluate a number of options when considering the sometimes daunting prospect of launching their product in Europe.

Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial. Pridopidine is an oral agonist of the S1R protein ...

After hours: February 14 at 6:47:01 PM EST Loading Chart for IQV ...